Does valsartan reduce acute cardiotoxic changes in humans receiving CHOP chemotherapy?
Valsartan may mitigate acute cardiotoxicity induced by CHOP chemotherapy, highlighting a potential role for ARBs in cardio-oncology.
The results indicate that angiotensin II may play an essential role in acute CHOP-induced cardiotoxicity in humans. Future long-term studies are necessary to judge whether ARBs have a potential to prevent the chronic or late-onset types of doxorubicin-induced cardiotoxicity.
Nakamae et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: